Finished product reference
Procarbazine
Capsule · Oral · 50 mg
- List code
- 1055
- Salt form
- Hydrochloride
- Pharmacologic class
- Antineoplastic (alkylating agent, methylhydrazine derivative)
What it is and how it works
Procarbazine is a prodrug activated in the liver to reactive metabolites that methylate DNA and inhibit DNA, RNA and protein synthesis. It also has weak monoamine oxidase inhibitory activity.
Indications
Hodgkin lymphoma (e.g. in BEACOPP or MOPP-type regimens) and other lymphomas; brain tumours such as gliomas (e.g. PCV regimen).
Dosage and administration (summary)
Dosing is by specialist oncology protocol, commonly about 100 mg/m² daily orally for 7–14 days of each cycle.
Contraindications
Pre-existing severe bone marrow suppression, severe hepatic or renal impairment, and pregnancy.
Warnings and precautions
Causes myelosuppression, nausea and vomiting; monitor blood counts. Alcohol may cause a disulfiram-like reaction and, because of MAO inhibition, tyramine-rich foods and sympathomimetic or serotonergic drugs should be avoided; it is carcinogenic and causes infertility.
Pregnancy
Contraindicated in pregnancy because of teratogenic risk; effective contraception is required.
Storage and supply
Store below 25 °C, protected from light and moisture; handle as a cytotoxic drug.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.